Compare CIGL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIGL | IFRX |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | Singapore | Germany |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.4M | 71.1M |
| IPO Year | 2025 | 2017 |
| Metric | CIGL | IFRX |
|---|---|---|
| Price | $1.72 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 20.9K | ★ 658.1K |
| Earning Date | 09-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,072,733.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.32 | N/A |
| 52 Week Low | $1.40 | $0.71 |
| 52 Week High | $31.06 | $2.77 |
| Indicator | CIGL | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 57.33 |
| Support Level | $1.55 | $0.99 |
| Resistance Level | $1.94 | $1.16 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 56.10 | 89.13 |
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.